Evidence map›Paper›PMID 36149437›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2022

Focal cavity radiotherapy after neurosurgical resection of brain metastases: sparing neurotoxicity without compromising locoregional control.

Klaus-Henning Kahl, Ehab Shiban, Susanne Gutser, Christoph J Maurer, Björn Sommer, Heiko Müller, Ina Konietzko, Ute Grossert, Ansgar Berlis, Tilman Janzen and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Klaus-Henning KahlKlink für Strahlentherapie und Radioonkologie, Universitätsklinikum Augsburg, Stenglinstr. 2, 86256, Augsburg, Germany. klaushenning.kahl@uk-augsburg.de.ORCID 0000-0002-0545-1367
Ehab ShibanKlinik für Neurochirurgie, Universitätsklinikum Augsburg, Augsburg, Germany.
Susanne GutserMedizinische Physik und Strahlenschutz, Universitätsklinikum Augsburg, Augsburg, Germany.
Christoph J MaurerKlinik für Diagnostische und Interventionelle Radiologie und Neuroradiologie, Universitätsklinikum Augsburg, Augsburg, Germany.
Björn SommerKlinik für Neurochirurgie, Universitätsklinikum Augsburg, Augsburg, Germany.
Heiko MüllerKlinik für Neurochirurgie, Universitätsklinikum Augsburg, Augsburg, Germany.
Ina KonietzkoKlinik für Neurochirurgie, Universitätsklinikum Augsburg, Augsburg, Germany.
Ute GrossertKlinik für Neurochirurgie, Universitätsklinikum Augsburg, Augsburg, Germany.
Ansgar BerlisKlinik für Diagnostische und Interventionelle Radiologie und Neuroradiologie, Universitätsklinikum Augsburg, Augsburg, Germany.
Tilman JanzenMedizinische Physik und Strahlenschutz, Universitätsklinikum Augsburg, Augsburg, Germany.
Georg StübenKlink für Strahlentherapie und Radioonkologie, Universitätsklinikum Augsburg, Stenglinstr. 2, 86256, Augsburg, Germany.
University Hospital Augsburg · DEAugsburg University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDoes focal cavity radiotherapy after resection of brain metastasis "spare" whole-brain radiotherapy, which is associated with toxicity for patients, through the complete course of their disease without compromising long-term local control of the brain?

methodsWe retrospectively analyzed outcomes of patients who underwent adjuvant focal cavity radiotherapy between 2014 and 2021 at our center.

resultsA total of 83 patients with 86 resected brain metastases were analyzed. 64% had singular, 36% two to four brain metastases. In cases with multiple metastases, omitted lesions were treated with radiosurgery. Median follow-up was 7.3 months (range 0-71.2 months), 1‑year overall survival rate was 57.8% (95% CI 44.9-68.8%). Radiotherapy was administered with a median biologically effective dose (α/β 10) surrounding the planning target volume of 48 Gy (range 23.4-60 Gy). Estimated 1‑year local control rate was 82.7% (95% CI 67.7-91.2%), estimated 1‑year distant brain control rate was 55.7% (95% CI 40.5-68.4%), estimated 1‑year leptomeningeal disease rate was 16.0% (95% CI 7.3-32.9%). Eleven distant brain recurrences could be salvaged with radiosurgery. In the further course of disease, 14 patients (17%) developed disseminated metastatic disease in the brain. Estimated 1‑year free of whole-brain radiotherapy rate was 72.3% (95% CI 57.1-82.9%). All applied treatments led to an estimated 1‑year neuro-control rate of 79.1% (95% CI 65.0-88.0%), estimated 1‑year radionecrosis rate was 23% (95% CI 12.4-40.5%).

conclusionIn our single-center study, focal cavity radiotherapy was associated with high local control. In three out of four patients, whole-brain radiotherapy could be avoided in the complete course of disease, using radiosurgery as salvage approach without compromising neuro-control.

Indexed as

Brain NeoplasmsRadiosurgeryCranial IrradiationHumansRadiotherapy, AdjuvantRetrospective StudiesSalvage TherapyLeptomeningeal diseaseRadionecrosisSRSWBRTWhole brain radiotherapy

Identifiers

PMID36149437
PMCPMC9700584
OpenAlexW4296793615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.